Want to see DE:FRE full AI Analyst Report?
FRE Stock Chart & Stats
€44.62
€0.28(0.81%)
At close: 4:00 PM EST
€44.62
€0.28(0.81%)
Day’s Range― - ―
52-Week Range€35.11 - €52.96
Previous CloseN/A
Volume90.82K
Average Volume (3M)750.62K
Market Cap
€23.73B
Enterprise Value€31.83B
Total Cash (Recent Filing)€2.06B
Total Debt (Recent Filing)€11.90B
Price to Earnings (P/E)16.0
Beta0.80
Next Earnings
Aug 05, 2026EPS Estimate
0.87Next Dividend Ex-DateN/A
Dividend Yield2.05%
Share Statistics
EPS (TTM)2.66
Shares Outstanding563,237,300
10 Day Avg. Volume787,875
30 Day Avg. Volume750,621
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)1.44
Price to Sales (P/S)1.21
P/FCF Ratio23.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€53.84Price Target Upside20.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)3.5
Revenue Forecast (FY)€23.62B
Bulls Say, Bears Say
Bulls Say
Profitability RecoveryProfitability has moved from a 2023 loss to sustained positive earnings and stronger margins, evidenced by net income rising and EBIT margin improvement. This recovery increases retained earnings, supports reinvestment and debt reduction, and makes earnings more resilient over a 2–6 month horizon.
Solid Free Cash FlowConsistent positive operating and free cash flow, with FCF at meaningful levels and conversion of ~44%–62% of net income, provides durable internal funding for capex, working capital, and debt servicing. Strong cash generation underpins financial flexibility and strategic execution.
Recurring Demand (dialysis)A core business built on recurring dialysis treatments and chronic-care services produces predictable utilization and reimbursement flows. That recurring revenue base, combined with product supply to care delivery, supports steady cash inflows and lowers revenue cyclicality over medium-term planning horizons.
Bears Say
Sizable Absolute DebtDespite improved leverage ratios, the company carries ~€11.9B of absolute debt which constrains financial flexibility. High nominal debt increases interest and refinancing risk, reducing capacity for acquisitions or buffer against operating shocks over the next several quarters.
Choppy Revenue TrajectoryMulti-year revenue instability signals structural headwinds or execution gaps. Inconsistent top-line trends make long-term planning harder, limit operating leverage benefits, and may indicate competitive pressures or pricing/reimbursement challenges that could persist into the medium term.
Volatile Cash Flow ProfileLarge swings in free cash flow year-to-year and modest operating cash flow margins versus revenue reduce predictability of funding for growth and deleveraging. This volatility can stress liquidity planning and limit ability to sustain investments or cover debt if adverse conditions reappear.
Fresenius SE & Co. KGaA News
FRE FAQ
What was Fresenius SE & Co. KGaA’s price range in the past 12 months?
Fresenius SE & Co. KGaA lowest stock price was €35.11 and its highest was €52.96 in the past 12 months.
What is Fresenius SE & Co. KGaA’s market cap?
Fresenius SE & Co. KGaA’s market cap is €23.73B.
When is Fresenius SE & Co. KGaA’s upcoming earnings report date?
Fresenius SE & Co. KGaA’s upcoming earnings report date is Aug 05, 2026 which is in 22 days.
How were Fresenius SE & Co. KGaA’s earnings last quarter?
Fresenius SE & Co. KGaA released its earnings results on May 06, 2026. The company reported €0.82 earnings per share for the quarter, missing the consensus estimate of €0.875 by -€0.055.
Is Fresenius SE & Co. KGaA overvalued?
According to Wall Street analysts Fresenius SE & Co. KGaA’s price is currently Undervalued.
Does Fresenius SE & Co. KGaA pay dividends?
Fresenius SE & Co. KGaA pays a Annually dividend of €1.05 which represents an annual dividend yield of 2.05%. See more information on Fresenius SE & Co. KGaA dividends here
What is Fresenius SE & Co. KGaA’s EPS estimate?
Fresenius SE & Co. KGaA’s EPS estimate is 0.87.
How many shares outstanding does Fresenius SE & Co. KGaA have?
Fresenius SE & Co. KGaA has 563,237,300 shares outstanding.
What happened to Fresenius SE & Co. KGaA’s price movement after its last earnings report?
Fresenius SE & Co. KGaA reported an EPS of €0.82 in its last earnings report, missing expectations of €0.875. Following the earnings report the stock price went up 1.139%.
Which hedge fund is a major shareholder of Fresenius SE & Co. KGaA?
Currently, no hedge funds are holding shares in DE:FRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fresenius SE & Co. KGaA Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€53.84 (20.67% Upside)
€53.84 (20.67% Upside)
Insider Transactions
Bought Shares
Worth €499.7K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
50.67%
12-Months-Change
Fundamentals
Return on Equity
7.76%
Trailing 12-Months
Asset Growth
-1.94%
Trailing 12-Months
Company Description
Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA operates as a diverse healthcare enterprise, supplying a comprehensive array of products and services primarily focused on dialysis, hospital management, and outpatient medical care. Its activities are structured across four main divisions: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care division is dedicated to individuals living with chronic kidney failure, offering essential items like dialyzers, hemodialysis machines, and related disposable supplies, alongside various dialysis-specific services. Fresenius Kabi concentrates on the therapeutic treatment and care of ill patients. Its extensive product range includes intravenous pharmaceuticals, such as generic drugs for oncology, anesthetics, pain relief, anti-infectives, and critical care. Additionally, it provides parenteral and enteral nutritional products, infusion solutions, and blood volume expanders for infusion therapy. The segment also develops biosimilars—biological medicines for autoimmune and cancer conditions—and manufactures medical devices and disposables crucial for administering IV generics, infusion treatments, and clinical nutrition. Transfusion products for blood component collection and corporeal therapies are also part of its offerings. Fresenius Helios manages significant healthcare operations, encompassing 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers throughout Germany. In Spain, its presence includes 49 hospitals, 88 outpatient clinics, and around 300 risk prevention centers. This segment also delivers fertility treatment services through 33 clinics and an additional 39 sites located across 10 countries on three continents. Finally, the Fresenius Vamed division specializes in project management and service delivery for hospitals and other healthcare facilities. Its offerings span project development, meticulous planning, and turnkey construction solutions. Furthermore, it provides ongoing maintenance, technical oversight, and operational management services. The company, initially known as Fresenius SE, officially changed its name to Fresenius SE & Co. KGaA in January 2011. Founded in 1912, Fresenius SE & Co. KGaA maintains its corporate headquarters in Bad Homburg vor der Höhe, Germany.
FRE Stock 12 Month Forecast
Average Price Target
€53.84
▲(20.67% Upside)
Technical Analysis
CompuGroup Medical
―
Draegerwerk AG & Co. KGaA
―
Fresenius Medical Care AG & Co. KGaA
―
MEDICLIN
―
RHON-KLINIKUM AG
―
Options Prices
Currently, No data available
---









